A Phase I, Open Label, Multi-center, Single Dose Study to Evaluate the Pharmacokinetics of LDE225 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function.

Trial Profile

A Phase I, Open Label, Multi-center, Single Dose Study to Evaluate the Pharmacokinetics of LDE225 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function.

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Feb 2017

At a glance

  • Drugs Sonidegib (Primary)
  • Indications Basal cell cancer; Chronic myeloid leukaemia; Pancreatic cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Novartis
  • Most Recent Events

    • 18 May 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Sep 2014 Planned End Date changed from 1 Jun 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov.
    • 01 Mar 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top